6 Dimensions Capital, the strategic investment vehicle formed by pharmaceutical firm WuXi PharmaTech and venture capital firm Frontline BioVentures, is raising up to $26m for an affiliates fund, according to a regulatory filing.
WuXi Healthcare Ventures, the corporate venture capital arm of WuXi PharmaTech, combined with Frontline in May 2017 to form US-based 6 Dimensions. The firm announced it was looking to raise $450m for its first US fund in October this year.
The affiliates fund is led by founding partners at WuXi Healthcare Ventures Edward Hu, Ge Li and Wei Li as well as Frontline Bioventures managing partners Leon Chen and Ching Zhu, according to the filing,.
6 Dimensions’ has approximately $800m of assets under management. It participated in a $57m series B round for cellular immunotherapy developer Medeor Therapeutics last month and co-led a $28m series B round for precision medicine researcher AnchorDX the same month.